Clinical Trials Browser

NCT04940286 2026-04-16

Gemcitabine, Nab-paclitaxel, Durvalumab, and Oleclumab Before Surgery for the Treatment of in Resectable/Borderline Resectable Primary Pancreatic Cancer

Phase 2 Active not recruiting

13 enrolled

Gastrointestinal

Pancreatic Neoplasms

NCT02465060 2026-04-13

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Phase 2 Active not recruiting

6,452 enrolled 2 FDA

BreastCNSDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidOther hematologic neoplasmPlasma cellThoracic

Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Glioma, Carcinoma, Hepatocellular, Lung Neoplasms, Lymphoma, Melanoma, Multiple Myeloma, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Rectal Neoplasms, Stomach Neoplasms, Thyroid Neoplasms, Uterine Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Hematologic Neoplasms

NCT04548752 2026-04-13

Testing the Addition of Pembrolizumab, an Immunotherapy Cancer Drug to Olaparib Alone as Therapy for Patients With Pancreatic Cancer That Has Spread With Inherited BRCA Mutations

Phase 2 Active not recruiting

88 enrolled

Gastrointestinal

Pancreatic Neoplasms

NCT05554367 2026-04-13

Palbociclib and Binimetinib in RAS-Mutant Cancers, A ComboMATCH Treatment Trial

Phase 2 Active not recruiting

199 enrolled

GastrointestinalGynecologic

Ovarian Neoplasms, Pancreatic Neoplasms

NCT04482309 2026-04-09

DPT02

Phase 2 Active not recruiting

477 enrolled 2 FDA

Gastrointestinal

Pancreatic Neoplasms, Colorectal Neoplasms

NCT05945823 2026-04-09

Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors

Phase 2 Active not recruiting

53 enrolled

Gastrointestinal

Adenocarcinoma Of Esophagus, Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms, Pancreatic Neoplasms

NCT05632328 2026-04-08

AGEN1423 and Botensilimab w/ or w/o Chemo in PDAC

Phase 2 Active not recruiting

24 enrolled

Gastrointestinal

Pancreatic Neoplasms

NCT03485209 2026-04-07

innovaTV 207

Phase 2 Active not recruiting

352 enrolled

GastrointestinalHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms

NCT03678883 2026-04-03

9-ING-41 in Patients With Advanced Cancers

Phase 2 Active not recruiting

350 enrolled

BreastCNSGastrointestinalGenitourinaryLymphoidOther hematologic neoplasmSarcomaThoracic

Bone Neoplasms, Breast Neoplasms, Glioma, Kidney Neoplasms, Lung Neoplasms, Lymphoma, Non-Hodgkin, Neoplasm Metastasis, Neoplasms, Hereditary Sensory and Autonomic Neuropathies, Pancreatic Neoplasms, Sarcoma, Colorectal Neoplasms, Leukemia-Lymphoma, Adult T-Cell

NCT04820179 2026-04-02

Atezolizumab + Cabozantinib in Patients w/ Metastatic, Refractory Pancreatic Cancer

Phase 2 Active not recruiting

30 enrolled

Gastrointestinal

Pancreatic Neoplasms

NCT04331041 2026-03-25

Stereotactic Body Radiotherapy and Focal Adhesion Kinase Inhibitor in Advanced Pancreas Adenocarcinoma

Phase 2 Active not recruiting

42 enrolled

Gastrointestinal

Pancreatic Neoplasms

NCT04233866 2026-03-23

Comparing Two Treatment Combinations, Gemcitabine and Nab-Paclitaxel With 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan for Older Patients With Pancreatic Cancer That Has Spread

Phase 2 Active not recruiting

176 enrolled

Gastrointestinal

Pancreatic Neoplasms

NCT03816163 2026-03-12

A Study of Zolbetuximab (IMAB362) in Adults With Pancreatic Cancer

Phase 2 Active not recruiting

393 enrolled

Gastrointestinal

Pancreatic Neoplasms

NCT02568267 2026-03-06

STARTRK-2

Phase 2 Active not recruiting

534 enrolled 2 FDA

BreastCNSDermatologicEndocrineGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidNETSarcomaThoracic

Thyroid Cancer, Papillary, Brain Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Head and Neck Neoplasms, Melanoma, Ovarian Neoplasms, Pancreatic Neoplasms, Salivary Gland Neoplasms, Sarcoma, Colorectal Neoplasms, Lymphoma, Large-Cell, Anaplastic, Cholangiocarcinoma, Neuroendocrine Tumors

NCT02890355 2026-03-05